Xiaoxue Zhu

发表

Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects

Xiaojiao Li, Hong Zhang, Haijing Wei, 2018, Cancer Chemotherapy and Pharmacology.

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers

J. Niu, D. Zhong, Wei Li, 2018, Front. Pharmacol..

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects

QUAN LIU, J. Niu, Xiaojiao Li, 2020, Frontiers in Pharmacology.

Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor

D. Zhong, Hongbin Sun, Yifan Zhang, 2020, British journal of clinical pharmacology.

Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, CNS Drugs.

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers

Haijing Wei, Yanhua Ding, Binhua Lv, 2020, Frontiers in Pharmacology.

Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator‐Activated Receptor Pan‐Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes

Z. Ning, Xiaojiao Li, Hong Zhang, 2020, Clinical pharmacology in drug development.

Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Frontiers in Pharmacology.

Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus

J. Niu, Xiaojiao Li, Hong Zhang, 2018, The Journal of pharmacy and pharmacology.

Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Clinical therapeutics.

HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial

Qianqian Wang, Yanhua Ding, Liang Zhou, 2023, Investigational New Drugs.

Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study

Yanhua Ding, Hong Wang, Cuiyun Li, 2021, Expert opinion on investigational drugs.

Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Antiviral research.

Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection

J. Niu, Xiaojiao Li, Hong Zhang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetic Profile of a Generic Formulation of Sofosbuvir and Its Metabolite GS‐331007 in Healthy Chinese Subjects

J. Niu, Xiaojiao Li, Hong Zhang, 2019, Clinical pharmacology in drug development.

First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults

Xiaojiao Li, Hong Zhang, Haijing Wei, 2021, Frontiers in Pharmacology.

Bioequivalence and Pharmacokinetic Profiles of Agomelatine 25-mg Tablets in Healthy Chinese Subjects: A Four-Way Replicate Crossover Study Demonstrating High Intra- and Inter-Individual Variations.

Y. Qiao, J. Niu, Hong Zhang, 2017, Chemical & pharmaceutical bulletin.

Dorzagliatin (HMS5552), a novel dual‐acting glucokinase activator, improves glycaemic control and pancreatic β‐cell function in patients with type 2 diabetes: A 28‐day treatment study using biomarker‐guided patient selection

Xiao-ying Li, Dalong Zhu, Yongguo Li, 2018, Diabetes, obesity & metabolism.

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Pharmacology research & perspectives.

Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Expert Opinion on Investigational Drugs.

Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial

Huanming Chen, Hui Lu, J. Niu, 2023, BMC Medicine.

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2018, Front. Pharmacol..

Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2018, Front. Pharmacol..

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Frontiers in Pharmacology.

First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2022, Frontiers in Pharmacology.

PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study

Li Yan, Yanhua Ding, Junyan Wu, 2022, BMC Medicine.

Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals

J. Niu, Xiaojiao Li, Hong Zhang, 2021, Expert opinion on investigational drugs.

A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter Type 2, in Healthy Individuals at Steady State.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Clinical therapeutics.

Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Diabetes, obesity & metabolism.

Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study

Huimao Zhang, J. Niu, Lei Zhang, 2022, Hepatology International.

ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2023, Nature communications.

Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects.

J. Niu, D. Brainard, Xiaojiao Li, 2018, Clinical therapeutics.

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men

X. Yang, Xiaojiao Li, Hong Zhang, 2021, Frontiers in Pharmacology.

A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Annals of medicine.

Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese Subjects

Yingjie Guo, Xiaojiao Li, Hong Zhang, 2020, Clinical pharmacology in drug development.

Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment

Shiping Ma, Chengluan Xuan, Xiaojiao Li, 2022, Annals of medicine.

Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus

Xiaojiao Li, Hong Zhang, Yan-hua Ding, 2021, Clinical pharmacology in drug development.

Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study

Hong Zhang, Yanhua Ding, Cuiyun Li, 2023, Annals of medicine.

Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in Chinese people with type 2 diabetes mellitus

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Diabetes, obesity & metabolism.